JP2018527323A5 - - Google Patents

Download PDF

Info

Publication number
JP2018527323A5
JP2018527323A5 JP2018503151A JP2018503151A JP2018527323A5 JP 2018527323 A5 JP2018527323 A5 JP 2018527323A5 JP 2018503151 A JP2018503151 A JP 2018503151A JP 2018503151 A JP2018503151 A JP 2018503151A JP 2018527323 A5 JP2018527323 A5 JP 2018527323A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
polypeptide
polypeptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018503151A
Other languages
English (en)
Japanese (ja)
Other versions
JP6866345B2 (ja
JP2018527323A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/043267 external-priority patent/WO2017015433A2/en
Publication of JP2018527323A publication Critical patent/JP2018527323A/ja
Publication of JP2018527323A5 publication Critical patent/JP2018527323A5/ja
Application granted granted Critical
Publication of JP6866345B2 publication Critical patent/JP6866345B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018503151A 2015-07-23 2016-07-21 Il−23a及びb細胞活性化因子(baff)を標的とする化合物及びその使用 Active JP6866345B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562196170P 2015-07-23 2015-07-23
US62/196,170 2015-07-23
US201562201067P 2015-08-04 2015-08-04
US62/201,067 2015-08-04
US201662355302P 2016-06-27 2016-06-27
US62/355,302 2016-06-27
PCT/US2016/043267 WO2017015433A2 (en) 2015-07-23 2016-07-21 Compound targeting il-23a and b-cell activating factor (baff) and uses thereof

Publications (3)

Publication Number Publication Date
JP2018527323A JP2018527323A (ja) 2018-09-20
JP2018527323A5 true JP2018527323A5 (enExample) 2019-08-08
JP6866345B2 JP6866345B2 (ja) 2021-04-28

Family

ID=57835236

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018503151A Active JP6866345B2 (ja) 2015-07-23 2016-07-21 Il−23a及びb細胞活性化因子(baff)を標的とする化合物及びその使用

Country Status (21)

Country Link
US (3) US10280231B2 (enExample)
EP (1) EP3322436A4 (enExample)
JP (1) JP6866345B2 (enExample)
KR (1) KR102644875B1 (enExample)
CN (1) CN108135976B (enExample)
AU (1) AU2016297575B2 (enExample)
BR (1) BR112018001255A2 (enExample)
CA (1) CA2993329A1 (enExample)
CL (1) CL2018000182A1 (enExample)
CO (1) CO2018001264A2 (enExample)
EA (1) EA201890360A1 (enExample)
IL (1) IL256665B2 (enExample)
MX (1) MX2018000959A (enExample)
MY (1) MY191081A (enExample)
PE (1) PE20180774A1 (enExample)
PH (2) PH12021552628A1 (enExample)
SA (1) SA518390788B1 (enExample)
SG (1) SG10201912593VA (enExample)
TW (2) TWI861413B (enExample)
UA (1) UA125433C2 (enExample)
WO (1) WO2017015433A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9963510B2 (en) 2005-04-15 2018-05-08 Macrogenics, Inc. Covalent diabodies and uses thereof
WO2012061448A1 (en) 2010-11-04 2012-05-10 Boehringer Ingelheim International Gmbh Anti-il-23 antibodies
US11078265B2 (en) 2012-05-03 2021-08-03 Boehringer Ingelheim International Gmbh Anti-IL-23 antibodies
WO2016014775A1 (en) 2014-07-24 2016-01-28 Boehringer Ingelheim International Gmbh Biomarkers useful in the treatment of il-23a related diseases
BR112017014684A2 (en) 2015-02-04 2018-01-09 Boehringer Ingelheim International Gmbh methods of treatment of inflammatory diseases
KR102644875B1 (ko) * 2015-07-23 2024-03-06 베링거잉겔하임인터내쇼날유한회사 Il-23a 및 b-세포 활성화 인자(baff)를 표적화하는 화합물 및 이의 용도
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
US20240400670A1 (en) * 2021-09-30 2024-12-05 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Anti-il23 antibody fusion protein and uses thereof
CN121039167A (zh) * 2022-12-28 2025-11-28 苏州创胜医药集团有限公司 包含抗baff抗体的双特异性结合蛋白及其用途
WO2025007943A1 (zh) * 2023-07-06 2025-01-09 荣昌生物制药(烟台)股份有限公司 用taci-fc融合蛋白治疗anca相关性血管炎的方法
WO2025170982A2 (en) * 2024-02-06 2025-08-14 Paragon Therapeutics, Inc. Il-23 antibody compositions and methods of use
CN119638823A (zh) * 2024-12-10 2025-03-18 中国医学科学院病原生物学研究所 检测a35r蛋白的单克隆抗体及其应用

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4880635B1 (en) 1984-08-08 1996-07-02 Liposome Company Dehydrated liposomes
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4921757A (en) 1985-04-26 1990-05-01 Massachusetts Institute Of Technology System for delayed and pulsed release of biologically active substances
US4920016A (en) 1986-12-24 1990-04-24 Linear Technology, Inc. Liposomes with enhanced circulation time
JPH0825869B2 (ja) 1987-02-09 1996-03-13 株式会社ビタミン研究所 抗腫瘍剤包埋リポソ−ム製剤
US4911928A (en) 1987-03-13 1990-03-27 Micro-Pak, Inc. Paucilamellar lipid vesicles
US4917951A (en) 1987-07-28 1990-04-17 Micro-Pak, Inc. Lipid vesicles formed of surfactants and steroids
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP2275449B1 (en) 2000-06-16 2016-09-28 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to BLyS
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
WO2012018687A1 (en) * 2010-08-02 2012-02-09 Macrogenics, Inc. Covalent diabodies and uses thereof
US9284375B2 (en) * 2005-04-15 2016-03-15 Macrogenics, Inc. Covalent diabodies and uses thereof
AU2006236439B2 (en) 2005-04-15 2012-05-03 Macrogenics, Inc. Covalent diabodies and uses thereof
CA2672229A1 (en) * 2006-12-14 2008-06-19 Actogenix N.V. Delivery of binding molecules to induce immunomodulation
MX2009013816A (es) 2007-06-21 2010-02-24 Macrogenics Inc Diacuerpos covalentes y usos de los mismos.
EP3211010A1 (en) 2007-12-21 2017-08-30 Medimmune Limited Binding members for interleukin-4 receptor alpha (il-4r) - 173
KR101603917B1 (ko) * 2008-05-09 2016-03-17 애브비 인코포레이티드 최종 당화 산물의 수용체(rage)에 대한 항체 및 이의 용도
CN102369021B (zh) 2008-12-19 2016-09-07 宏观基因有限公司 共价双抗体及其用途
US20130129723A1 (en) 2009-12-29 2013-05-23 Emergent Product Development Seattle, Llc Heterodimer Binding Proteins and Uses Thereof
GB201002238D0 (en) 2010-02-10 2010-03-31 Affitech As Antibodies
PL2536745T3 (pl) * 2010-02-19 2017-01-31 Xencor, Inc. Nowe immunoadhezyny CTLA4-IG
EP2550529B1 (en) 2010-03-23 2021-11-17 Iogenetics, LLC. Bioinformatic processes for determination of peptide binding
TWI426920B (zh) 2010-03-26 2014-02-21 Hoffmann La Roche 雙專一性、雙價抗-vegf/抗-ang-2抗體
WO2012061448A1 (en) * 2010-11-04 2012-05-10 Boehringer Ingelheim International Gmbh Anti-il-23 antibodies
GB201020738D0 (en) * 2010-12-07 2011-01-19 Affitech Res As Antibodies
CN103429261A (zh) 2010-12-22 2013-12-04 塞法隆澳大利亚股份有限公司 半寿期改进的修饰抗体
MX348071B (es) * 2011-03-16 2017-05-26 Amgen Inc Variantes de fc.
TWI803876B (zh) * 2011-03-28 2023-06-01 法商賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
SI2814587T1 (en) 2012-02-15 2018-08-31 F. Hoffmann-La Roche Ag Affinity chromatography based on the Fc receptor
GB201203071D0 (en) * 2012-02-22 2012-04-04 Ucb Pharma Sa Biological products
AR090626A1 (es) * 2012-04-20 2014-11-26 Lilly Co Eli Anticuerpos anti-baff-anti-il-17 biespecificos
CN104884473B (zh) * 2012-05-22 2019-12-03 百时美施贵宝公司 Il-17a/f il-23双特异性抗体及其应用
KR102181776B1 (ko) * 2012-06-05 2020-11-24 삼성전자주식회사 범용 디바이스에서의 파일 송/수신 장치 및 방법
WO2014100490A1 (en) 2012-12-19 2014-06-26 Adimab, Llc Multivalent antibody analogs, and methods of their preparation and use
JP2015088330A (ja) * 2013-10-30 2015-05-07 トヨタ自動車株式会社 硫黄含有全固体電池
US10435474B2 (en) * 2013-12-24 2019-10-08 Ossianix, Inc. Baff selective binding compounds and related methods
EA033604B1 (ru) * 2014-01-31 2019-11-08 Boehringer Ingelheim Int Молекула анти-baff антитела, фармацевтическая композиция, содержащая эту молекулу, способы ее применения и кодирующий ее изолированный полинуклеотид
KR102644875B1 (ko) * 2015-07-23 2024-03-06 베링거잉겔하임인터내쇼날유한회사 Il-23a 및 b-세포 활성화 인자(baff)를 표적화하는 화합물 및 이의 용도

Similar Documents

Publication Publication Date Title
JP2018527323A5 (enExample)
JP6703560B2 (ja) 静電的ステアリング(electrostatic steering)効果を用いた抗体Fcヘテロ二量体分子を作製するための方法
RU2019120720A (ru) Улучшенные отдельные вариабельные домены иммуноглобулина, связывающиеся с сывороточным альбумином
HRP20191968T1 (hr) Monoklonska protutijela protiv klaudina-18 za liječenje karcinoma
JP2020508655A5 (enExample)
JP2012514997A5 (enExample)
JP2015528003A5 (enExample)
JP2017509335A5 (enExample)
JP2019525738A5 (enExample)
RU2016139022A (ru) МУЛЬТИМЕРНЫЕ Fc-БЕЛКИ
JP2016507525A5 (enExample)
JP2017504578A5 (enExample)
JP2020515518A5 (enExample)
JP2016508153A5 (enExample)
JP2017512063A5 (enExample)
RS65405B1 (sr) Multispecifična antitela koja olakšavaju selektivno uparivanje lakih lanaca
BR112015000798A2 (pt) heterodímeros assimétricos biespecíficos compreendendo construtos anti-cd3
JP2021500348A (ja) 単一特異性抗体から多重特異性抗体を生成させるための方法
AU2018277301A1 (en) Heterodimerizing Ig domains
BR112021000416A2 (pt) Composições e métodos relacionados a construtos do domínio de ligação fc-antígeno manipulado direcionado a cd38
IL302575A (en) IL-2R BETA GAMMA c BINDING COMPOUNDS AND USES THEREOF
KR20230118612A (ko) 헤테로다이머화를 위한 직교 돌연변이
RU2009126545A (ru) МУЛЬТИМЕРНЫЕ ПОЛИПЕПТИДЫ Fc-РЕЦЕПТОРА, ВКЛЮЧАЮЩИЕ МОДИФИЦИРОВАННЫЙ Fc-ДОМЕН
NZ738942B2 (en) Compound targeting il-23a and b-cell activating factor (baff) and uses thereof
NZ738942A (en) Compound targeting il-23a and b-cell activating factor (baff) and uses thereof